Abivax SA (ABVX) Stock Analysis
Verdict: HOLD
Positive Phase 3 safety data and a massive $800M capital raise de-risk the path to 2029 profitability, despite extreme short-term froth.
Investment score: 64/100
Analysis as of
Is Abivax SA stock worth reviewing? The TradeMates thesis
The model upgrades ABVX to a speculative BUY following major de-risking events. Positive clinical data combined with an $800M cash infusion provides a clear, funded path to commercialization, making the company a primary M&A target in the IBD space.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 75/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
Abivax SA opportunities and risks
What speaks for ABVX
- Phase 3 De-risking of Obefazimod
What speaks against ABVX
- Binary Trial Outcome Dependence
Peers and competitors
- ABVX.PA
- NANO.PA
- DBV.PA
- IVA.PA
- GNFT.PA
Frequently asked questions about Abivax SA (ABVX)
Is ABVX stock a good investment?
The TradeMates model rates Abivax SA as HOLD with an investment score of 64/100. The model upgrades ABVX to a speculative BUY following major de-risking events. Positive clinical data combined with an $800M cash infusion provides a clear, funded path to commercialization, making the company a primary M&A target in the IBD space. This is algorithmic model output, not personal investment advice.
Is ABVX stock a buy?
The TradeMates model verdict for ABVX is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.